Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Gatto

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Endocrinology and Metabolism|November 22, 2022
Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary TumorsFederico Gatto, Richard A Feelders, Peter M van Koetsveld, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2018
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 ExpressionAmmar Muhammad, Eva C Coopmans, Federico Gatto, et al.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2024
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1Diego Ferone, Pamela Freda, Laurence Katznelson, et al.
European Journal of Endocrinology|June 1, 2021
Global epidemiology of acromegaly: a systematic review and meta-analysisSalvatore Crisafulli, Nicoletta Luxi, Janet Sultana, et al.
Clinical Endocrinology|August 19, 2011
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatinsFederico Gatto, Federica Barbieri, Monica Gatti, et al.
Neuroendocrinology|July 26, 2016
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with PegvisomantSanne E Franck, Federico Gatto, Aart Jan van der Lely, et al.
European Journal of Endocrinology|February 19, 2016
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegalyFederico Gatto, Nienke R Biermasz, Richard A Feelders, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary AdenomasFederico Gatto, Richard A Feelders, Sanne E Franck, et al.
European Journal of Endocrinology|July 27, 2022
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation studyClaudia Campana, Peter M van Koetsveld, Richard A Feelders, et al.
Endocrinology|October 31, 2013
β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegalyFederico Gatto, Richard Feelders, Rob van der Pas, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Endocrinology and Metabolism|November 22, 2022
Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary TumorsFederico Gatto, Richard A Feelders, Peter M van Koetsveld, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2018
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 ExpressionAmmar Muhammad, Eva C Coopmans, Federico Gatto, et al.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2024
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1Diego Ferone, Pamela Freda, Laurence Katznelson, et al.
European Journal of Endocrinology|June 1, 2021
Global epidemiology of acromegaly: a systematic review and meta-analysisSalvatore Crisafulli, Nicoletta Luxi, Janet Sultana, et al.
Clinical Endocrinology|August 19, 2011
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatinsFederico Gatto, Federica Barbieri, Monica Gatti, et al.
Neuroendocrinology|July 26, 2016
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with PegvisomantSanne E Franck, Federico Gatto, Aart Jan van der Lely, et al.
European Journal of Endocrinology|February 19, 2016
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegalyFederico Gatto, Nienke R Biermasz, Richard A Feelders, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary AdenomasFederico Gatto, Richard A Feelders, Sanne E Franck, et al.
European Journal of Endocrinology|July 27, 2022
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation studyClaudia Campana, Peter M van Koetsveld, Richard A Feelders, et al.
Endocrinology|October 31, 2013
β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegalyFederico Gatto, Richard Feelders, Rob van der Pas, et al.
Pageof 8